Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Noble Corporation plc (NE) Price & Performance

Incyte CorporationTrade
Noble Corporation plcTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Noble Corporation plc — how do they compare? Incyte Corporation trades at $121.47 (market cap $24.54B), while Noble Corporation plc trades at $44.39 (market cap $7.10B). The key difference: Incyte Corporation is far larger — about 3.5× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.5% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYNE
Market Cap
$24.54B$7.10B
Sector
HealthTechnology
52-Week High
$129.93$54.37
52-Week Low
$81.61$26.61
Enterprise Value
$20.04B$8.53B
Dividend Yield
4.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.

Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.

Noble Corporation plc

Noble Corporation (NE) trades at $44.48, up 2.14% today, with a bullish technical signal driven by moving averages. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss, while revenue and net income have declined year-over-year. Recent news highlights multiple law firm investigations into the company, adding uncertainty. The consensus price target is $46.00, slightly above the current price, with analysts divided between Buy (31%) and Hold (43%) ratings.

The outlook is cautious due to earnings volatility and legal scrutiny, though positive cash flow and a solid backlog of $6.8 billion provide some stability. Key risks include operational suspensions and investor litigation, while potential upside hinges on execution improvements and contract wins. The stock's valuation appears stretched with a P/E of 47.32, demanding strong future growth to justify current levels.

Returns comparison

Trailing returns across standard periods

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Noble Corporation plc

Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.

Read more on NE